Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 56 million to 72.8 million yuan, representing a year-on-year growth of 388.29% to 534.78% [1] Financial Projections - The projected net profit attributable to shareholders for 2025 is between 56 million and 72.8 million yuan, with a non-GAAP net profit forecasted at 43 million to 61 million yuan, indicating a turnaround from losses [1] - The company anticipates a total of approximately 30 million yuan in asset impairment and credit impairment losses for the year [1] Business Strategy and Growth - The company plans to leverage its innovative therapies and expand its product line to enhance sales and market penetration, particularly in the orthopedic sector, where it is a leading player [1] - The ultrasound knife business is expected to see rapid growth in both sales and net profit in 2025 [1] - The international business, particularly through its subsidiary Implanet, is projected to achieve revenue of 1,247.39 million euros, a year-on-year increase of 32.62%, with the U.S. market showing a remarkable growth of 49.30% [1] Product Development and Market Expansion - The company aims to expedite the registration of innovative products such as the intelligent surgical robot and porous polyether ether ketone interbody fusion device in China [1] - There is a focus on increasing the penetration of the ultrasound knife business and promoting integrated product series in various surgical departments [1] - The company is committed to advancing its strategic business layout and ensuring the timely approval of its innovative products in the U.S. market by 2026 [1] Equity Incentive Plan - The company will introduce an equity incentive plan in 2025, with an estimated share-based payment expense of approximately 8.4 million yuan for the year [1]

中国经济网北京1月28日讯 三大股指涨跌不一，创指午后回落翻绿。截至收盘，上证指数报4151.24点，涨幅0.27%，成交额13655.26亿元；深证成指报 14342.89点，涨幅0.09%，成交额15998.84亿元；创业板指报3323.56点，跌幅0.57%，成交额7441.76亿元。 板块方面，贵金属、油气开采及服务、工业金属等板块涨幅居前，光伏设备、医疗服务、医疗器械等板块跌幅居前。 | 序号 | 板块 | 涨跌幅(%)▼ | | 总成交量 (万手) ▼ 总成交额 (亿元) ▼ | 净流入 (亿元) ▼ | 上涨家数 | 下跌多 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 音等屋 | 10.74 | 1387.18 | 453.36 | 21.93 | 11 | o | | 2 | 油气开采及服 | 7.54 | 3076.39 | 254.01 | 24.76 | 20 | o | | | ਡੇ | | | | | | | | 3 | 工亦等選 | 6.24 | 9201.81 | 1552.80 | 70.55 | ਦੇਤੋ ...

Group 1 - The core point of the news is that Aomei Medical's stock price dropped by 5% to 12.16 yuan per share, with a trading volume of 193 million yuan and a turnover rate of 3.47%, resulting in a total market capitalization of 7.701 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 3.677 billion yuan, and has achieved a year-to-date return of 8.42%, ranking 1994 out of 5549 in its category [2] - The fund has a one-year return of 14.06%, ranking 3672 out of 4285, and has experienced a cumulative loss of 47.1% since its inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 169 days, managing a total fund size of 5.205 billion yuan [3] - During the tenure of the fund manager, the best fund return was 103.17%, while the worst return was -30.27% [3]

Market Performance - The three major A-share indices showed mixed results, with the Shanghai Composite Index rising by 0.27% to close at 4151 points, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [1] - The total market turnover reached 2.99 trillion yuan, an increase of 70.8 billion yuan compared to the previous trading day, with over 3600 stocks declining [1] Sector Performance - Precious metals, including gold, saw significant gains, with spot gold surpassing 5200 USD for the first time, leading to multiple stocks like Zhongjin Gold and Chifeng Jilong Gold hitting the daily limit [1] - The non-ferrous metals sector experienced a surge, with stocks such as Silver Nonferrous and Chang Aluminum also reaching the daily limit [1] - The genetically modified sector rose, with Nongfa Seed Industry hitting the daily limit [1] - The automotive dismantling sector saw gains, with Feinan Resources rising by 20% [1] - Other sectors with notable increases included titanium dioxide, coal chemical, and phosphorus chemical industries [1] Declining Sectors - The biopharmaceutical and smallpox virus prevention sectors faced declines, with Baipusais falling over 10% [1] - The medical device sector also dropped, with Zhijiang Biological decreasing by over 8% [1] - The photovoltaic sector weakened, with Gaoce shares falling by over 8% [1] - Other sectors with significant declines included aerospace, decoration, and CRO industries [1] Top Gainers and Fund Inflows - Precious metals led the gainers with a 6.76% increase, followed by energy equipment at 6.10% and basic metals at 4.90% over the past five days [2] - The oil and natural gas sector rose by 3.64%, while coal and petroleum chemicals also saw increases of 3.29% and 3.23% respectively [2]

（文章来源：每日经济新闻） 1月28日医疗器械板块震荡调整，之江生物、万孚生物、迪安诊断、圣湘生物、三友医疗跌幅超5%，医疗器械ETF（562600）下跌2.18%。 从指数月线位置来看，医疗器械指数当前处在上一波熊牛转换起点附近，价格仍属相对低位，建议逢低关注。 ...

Core Viewpoint - Yongsheng Medical (01612) has experienced a stock price increase of over 9% following the announcement of a positive earnings forecast, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Group 1: Earnings Forecast - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Group 2: Reasons for Growth - The board attributes the significant increase in revenue to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross profit margins [1]

每经AI快讯，1月28日，据国家药监局官网消息，为满足监管急需，助推采用脑机接口技术的医疗器械 高质量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重 建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目 立项。 ...

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 截至2026年1月28日 13:15，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 1.70%，兴齐眼药上涨1.39%，艾力斯上涨0.67%；英科医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 东海证券指出，商务部等九部门联合印发的关于促进药品零售行业高质量发展的意见，从转型、支付、 供应、整合四大维度构建行业发展框架，推动行业从"单一卖药"向"健康服务"转型。政策明确鼓励兼并 重组与横向并购，叠加医保定点待遇与基层医疗机构平权、医保个人账户家庭共济等举措，将加速单体 药店出清，行业集中度有望加速提升；优化外配处方审核，打通线下药店处方堵点，允许企业自建药学 服务平台，加速处方外流和市场扩容；鼓励零售药店扩大经营范围，开展健康咨询、中医药文化、养老 照护、便民零售等，打造综合健康服务体。建议关注资金实力雄厚、并购整合能力强，合规运营与精细 ...

迈克生物（300463.SZ）1月28日在投资者互动平台表示，对于近期印度尼帕病毒，公司目前暂无已获证 的尼帕病毒检测产品。公司将根据产品战略规划，从临床需求紧迫性、技术实现可行性、注册程序合规 性等多个维度进行合理评估，审慎决策，同时严格履行信息披露义务。请您关注官方信息披露渠道，谨 慎投资，注意风险。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：近期印度尼帕病毒凶猛来袭，正直年底人员流动性 大，公司有针对该病毒检测试剂相关技术储备吗？ ...

Core Viewpoint - Jiuan Medical's 2025 performance forecast indicates a net profit of 2.02 to 2.35 billion yuan, representing a year-on-year growth of 21.05% to 40.83% [2][3]. Group 1: Performance Overview - The company expects to maintain a high profit level in 2025, with net profit projected to exceed 2 billion yuan, significantly above pre-pandemic levels [6]. - This voluntary performance forecast, although unaudited, signals Jiuan Medical's strong profitability for 2025 [6]. Group 2: Revenue and Profit Discrepancy - Despite the profit growth, Jiuan Medical's revenue is under pressure, with a notable decline in revenue from government orders related to the pandemic and a significant drop in sales of testing kits [5][6]. - The company's operating revenue for the current period is reported at approximately 765 million yuan, down 43.35% from the previous year [7]. Group 3: Profit Sources - The increase in net profit is primarily attributed to the performance of the asset management business and stable demand for testing kits and home healthcare electronic products [11]. - Investment income and fair value changes are becoming increasingly significant in the profit structure, indicating a shift from reliance on medical product sales to asset management and investment returns [13]. Group 4: Structural Implications - Jiuan Medical's current business model is evolving into a hybrid structure that combines healthcare product sales with substantial financial asset management capabilities [14][15]. - This structural change suggests that profit stability is more dependent on asset allocation performance rather than solely on product sales or market demand [16]. Group 5: Industry Context - Jiuan Medical's performance forecast represents a non-typical profit model within the healthcare industry, highlighting the need for market participants to differentiate between traditional growth paths and those driven by asset management capabilities [19]. - The sustainability of this profit structure and its resilience to market fluctuations will require further analysis following the annual report [19].